以下文章来源于格隆汇交易学苑 ，作者格隆汇小编 Hims&Hers(HIMS)曾被视为一个危险的"赌徒"。它利用监管漏洞在"药王"诺和诺德(NVO)的领地上疯狂试 探，股价也随之在暴涨与暴跌间反复横跳。 然而， 2026年3月9日，随着 HIMS正式宣布与诺和诺德达成全面和解，这场长达两年的"猫鼠游戏"画上了句号。这一事件也标志着长期 困扰该公司的"尾部风险"基本出清。 格隆汇交易学苑 . 以基本面为基础，专注于趋势交易 作者 | 格隆汇小编 数据支持 | 勾股 大数 据（www.gogudata.com） 在 美 股 医 疗 赛 道 ， 受此利好提振， HIMS股价爆发 出惊人的上涨动能，自3月9日以来，短短几天内涨幅已高达51%，市场正用真金白银为其从"灰色地带"跨 入"主流殿堂"重新定价。 01 恩怨录：从"生死局"到"投名状" 回顾 HIMS与诺和诺德的对抗 史，简直是一部现实版的《监管套利指南》： 战略对抗期（ 2024-2025）： 游击战与法律围剿 利用 FDA"短缺名单"的合规漏 洞，HIMS于2024年5月20日正式宣布在其平台上推出复合西马鲁肽注射剂。它以约$199的价格， 冲击着 诺和诺 ...

医药行业|行业研究报告 证券研究报告 2026/03 小核酸行业系列报告（一）：小核酸成药之路 —— Listening to the Sound of Silence: The Road to RNA Therapeutics 戎晓婕 S1190525070001 证券分析师： 分析师登记编号： 周豫 S1190523060002 证券分析师： 分析师登记编号： 核心观点 请务必阅读正文之后的免责条款部分 守正 出奇 宁静 致远 ◼ 小核酸药物通过RNA层面调控打开传统药物难以触达的靶点空间，已完成从技术验证到商业兑现的 跨越。2025年主要ASO、siRNA上市药物销售额分别约31亿美元、42亿美元。 ◼ 机制差异塑造了两条发展路径。ASO为单链结构，可通过鞘内给药/Gymnosis机制实现裸ASO进入目 标组织细胞，率先突破CNS、肌肉等领域，疗效提升依赖于化学修饰对分子稳定性与亲和力的优化； siRNA为双链形式，结构相对稳定但分子量较大且带强负电荷，需要依托载体实现有效递送；RISC 介导的催化切割赋予更强沉默效率，GalNAc技术成熟后，siRNA在肝靶向实现弯道超越。 ◼ 化学修饰历经四代迭代， ...

药渡每周渡选 26年3月2日-3月8日 药渡团队 药渡经纬信息科技（北京）有限公司 https://data.pharmacodia.com/ 目录 全 球生 物 医药 行业 动 态 全 球生 物 医药 行业 重大事件 全 球创 新 药 重 要 临 床 进 展/ 结果 全 球 创 新 药重要 投融资与交易 事 件 全球 医药 监 管动 态 （批 准上市 / I N D / 特 殊 审 评 ） 01全球生物医药行业动态 资本市场方面：产业合作与融资并购密集落地：德琪医药将 CD3/CD19 双抗全球权益授权优时比，最高获 11.8 亿美元；中国生 物制药与赛诺菲就罗伐昔替尼达成独家授权，最高可获 15.3 亿美元；齐鲁制药与爱科百发达成多动症新药合作，后者最高获 4.7 亿元里程碑付款。Candid 通过合并上市完成 5.05 亿美元融资，五和博澳递交港交所招股书拟上市。质肽生物、新码生物分别完 成超 5 亿、6.29 亿人民币融资，莱芒生物、易慕峰各获近 2 亿融资，深度智耀三月累计融资 1.5 亿美元，多家生物企业完成不同 轮次融资，黑石 4 亿美元押注梯瓦制药单抗研发。 临床进展方面：代谢、肿瘤、免疫等领 ...

Company Performance - Novo Nordisk's stock price decreased by 2.09% to $38.02, underperforming the S&P 500's daily loss of 1.52% [1] - Over the past month, shares have depreciated by 20.33%, significantly worse than the Medical sector's loss of 3.1% and the S&P 500's loss of 2.25% [1] Financial Projections - The upcoming earnings per share (EPS) for Novo Nordisk is projected at $0.86, indicating a 6.52% decrease from the same quarter last year [2] - The Zacks Consensus Estimate for revenue is $11.23 billion, reflecting a 1.99% increase from the previous year [2] - For the full year, projected earnings are $3.33 per share and revenue is $43.91 billion, representing declines of 15.91% and 6.13% respectively from the prior year [3] Analyst Estimates and Rankings - Recent changes to analyst estimates for Novo Nordisk are crucial for investors, as positive revisions can indicate a favorable business outlook [3] - The Zacks Rank system, which evaluates estimate changes, currently ranks Novo Nordisk at 4 (Sell), with the EPS estimate moving 0.36% lower over the past month [5] Valuation Metrics - Novo Nordisk's Forward P/E ratio is 11.68, which is lower than the industry average Forward P/E of 15.66 [6] - The Large Cap Pharmaceuticals industry, part of the Medical sector, has a Zacks Industry Rank of 205, placing it in the bottom 17% of over 250 industries [6]

Core Viewpoint - Hims & Hers has transitioned from compounded GLP-1 drugs to selling branded Wegovy and Ozempic directly, resolving legal issues and restoring investor confidence, leading to a significant stock price rebound of 64% since the announcement [1][2] Group 1: Company Developments - Hims & Hers agreed to sell branded Wegovy and Ozempic while discontinuing most compounded GLP-1 advertising, resolving a patent lawsuit with Novo Nordisk [1] - The company had seen its shares drop over 75% due to regulatory scrutiny and legal challenges but has now regained legitimacy with the new distribution rights [1] - The pivot to branded products enhances Hims' credibility as a healthcare partner and removes concerns about counterfeit safety and patent violations [1] Group 2: Market Response - Following the announcement, Hims' stock surged by 64%, including a remarkable 40% gain in a single day [1] - Analysts have responded positively, with Needham upgrading its rating to Buy with a target price of $30, while other firms have raised their price targets [1] - Revenue projections for Hims are robust, with expectations of $2.35 billion in 2025, reflecting a 59% year-over-year increase [1] Group 3: Risks and Challenges - Despite the positive developments, Hims is now heavily reliant on Novo Nordisk as a single supplier for its growth, which poses risks if production issues arise or if Novo changes its strategy [1][2] - The stock's current valuation is high, and analysts caution that any issues with patient retention or slower adoption of branded products could negatively impact share prices [1] - Historical context shows that previous collaborations with Novo have faced challenges, raising concerns about the sustainability of the current partnership [1]

This article seeks to analyze whether Hims and HERS Health, Inc. (HIM) stock is overpriced due to the short-term euphoria resulting from its remarriage with Novo Nordisk and short-covering, or undervalued by Mr. Market because of the perceived instability ofI run my own boutique law firm, focusing on investment transactions and disputes. Trained at top U.S. law schools and leading Wall Street law firms, I write here primarily to sharpen my own thinking and to engage with my followers. I endeavor to respond ...

365亿美元 VS 361亿美元。 2025年全球"药王"终极对决，落下帷幕。礼来替尔泊肽以4亿美元的微弱优势，硬生生把诺和诺德司美格鲁肽拽下王座。两款GLP-1减肥 药包揽冠亚军，蝉联两年销冠的默沙东K药，直接被挤出头部梯队。 谁能想到，这场千亿赛道的狂欢，起点竟是马斯克 2021年的一条社交动态。一张带货照，把司美格鲁肽从小众降糖药，捧成风靡全球的减肥神药，诺和诺德躺着 吃了三年先发红利。短短五年，王座易主，行业彻底洗牌。 就在所有人笃定，减肥药战场注定是礼来、诺和诺德双雄垄断，旁人连喝汤的份都没有时， 2026年早春，一个"掉队者"杀疯了—— 辉瑞 。 自研管线全线崩盘， GLP-1赛道彻底缺席，这个177岁的老牌巨头，凭什么敢硬闯双雄壁垒？放着全球市场不深耕，偏偏把首款减肥药的命运，全盘押注中国？ 01 双雄崩盘，辉瑞突袭： GLP-1格局彻底改写 2026年2月23日，诺和诺德遭遇股灾。股价暴跌超15%，创下近五年最大跌幅，市值单日蒸发数百亿美元，华尔街一片哗然。 导火索很扎心：旗下下一代减肥神药 CagriSema，84周减重23.0%，直接被礼来替尔泊肽25.5%的成绩碾压，连"不劣于"的底线都 ...

Total Income and Investment Returns in 2025 were DKK 21 billion (€2.8 billion). For 2025, Total Income and Investment Returns consisted of Income from dividends from the Novo Group companies (DKK 15 billion or €2.0 billion) and Returns from the Investment Assets Portfolio1 (DKK 5.8 billion or €0.8 billion).Novo Holdings generated returns on the Investment Portfolio2 of 2.3% in DKK, and 9.2% in Constant Exchange Rates (CER). The return for 2024 in CER was 14.8%. Novo Holdings’ 5- and 10-year returns are at 8 ...

Hello, I'm Ozmpic. >> GLP1s are everywhere. Micro do GLP1.From ripping through Hollywood, I'm on road to Super Bowl commercials. Many have called the drugs a medical miracle. >> It is in fact a miracle.>> In hopes of finally making progress in America's obesity crisis. And today, adding to the mounting evidence that these drugs could have benefits besides weight loss, a new study finding a 37% lower risk of death in patients with metastatic brain cancer. But the economic miracle that once seemed a sure bet, ...

The FDA has issued a warning letter to the maker of Ozimpic and WGOI. The agency says Nova Nordisk failed to report potential side effects in patients who took its blockbuster medications. The FDA cited three deaths among the patients, including one who died by suicide.The agency says the company did not report the deaths within the agency's required time frame, and that it also failed to investigate or report the suicide. In a statement, Nova Nordisk said it has been working diligently to address the FDA's ...